Sie sind bereits registriert?
Loggen Sie sich mit Ihrem Universimed-Benutzerkonto ein:
Sie sind noch nicht registriert?
Registrieren Sie sich jetzt kostenlos auf universimed.com und erhalten Sie Zugang zu allen Artikeln, bewerten Sie Inhalte und speichern Sie interessante Beiträge in Ihrem persönlichen Bereich zum späteren Lesen. Ihre Registrierung ist für alle Unversimed-Portale gültig. (inkl. allgemeineplus.at & med-Diplom.at)
Screening for Pancreatic Cancer in CDKN2A Mutation Carriers
Although population-wide screening for pancreatic cancer is not recommended, data are emerging to support surveillance of high-risk individuals to identify disease at an early stage (NEJM JW Oncol Hematol Dec 2022 and J Clin Oncol 2022; 40:3257). Among individuals with significantly increased risk for pancreatic cancer who may be candidates for screening include those with a germline pathogenic variant in CDKN2A.
To address the potential benefit of screening in this population, investigators in the Netherlands now report results of a prospective, 20-year, pancreatic cancer surveillance program (initiated in 2000) involving 347 germline CDKN2A pathogenic variant carriers. Of this cohort, the median age was 49, 58% were female, 38% had a first-degree relative with pancreatic cancer, 35% had a second-degree relative with pancreatic cancer, and 55% had a personal history of melanoma. Testing consisted of annual MRI cholangiopancreatography and, since 2012, inclusion of optional endoscopic ultrasound annually, alternating with MRI every 6 months.
Results at a median follow-up of 5.6 years were as follows:
- 36 cases of pancreatic cancer were detected in 31 patients (9%).
- 23% of cancers were diagnosed at first screening, and 81% were detected by MRI.
- 16% of patients had a second primary pancreatic cancer up to 9 years after the first diagnosis.
- 75% of cancers were resected, and 33% were stage I.
- 5-year overall survival (OS) was 32% among all patients and 44% among resected patients.
- Patients with stage I resectable disease had a 3-year OS of 83%.
- 3% had surgery for suspected malignancy but were found not to have pancreatic cancer.
This large retrospective series indicates a relatively high incidence of pancreatic cancer in CDKN2A mutation carriers with encouraging survival in resected stage I patients. These findings support the use of pancreatic cancer surveillance in this high-risk population.
Klatte DCF et al.
Title: Pancreatic cancer surveillance in carriers of a germline CDKN2A pathogenic variant: Yield and outcomes of a 20-year prospective follow-up.
Source: J Clin Oncol 2022 Oct 1; [e-pub]. (Abstract/FREE Full Text)